Lataa...
Optimizing Combination Therapies with Existing and Future CML Drugs
Small-molecule inhibitors imatinib, dasatinib and nilotinib have been developed to treat Chromic Myeloid Leukemia (CML). The existence of a triple-cross-resistant mutation, T315I, has been a challenging problem, which can be overcome by finding new inhibitors. Many new compounds active against T315I...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Public Library of Science
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2925944/ https://ncbi.nlm.nih.gov/pubmed/20808800 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0012300 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|